

# THE IMPACT OF COVID-19 ON THE INCIDENCE OF RECTAL CANCER IN KAZAKHSTAN: RESULTS OF COMPONENT ANALYSIS

Zh.B. TELMANOVA<sup>1-3</sup>, A.K. AXARIN<sup>1-4</sup>, A.O. ORALBEK<sup>5</sup>, S.T. OROZBAEV<sup>2</sup>,  
K.T. KULAYEV<sup>5</sup>, N.Z. SHAPAMBAYEV<sup>5</sup>, Y.K. KUANDYKOV<sup>5</sup>, Z.A. BILALOVA<sup>1</sup>,  
G.S. IGISSINOVA<sup>6,1</sup>, K.R. RUSTEMOVA<sup>2,1</sup>, I.O. KUDAIBERGENOVA<sup>4,3</sup>, N.S. IGISSINOV<sup>1-3</sup>

<sup>1</sup>Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan;

<sup>2</sup>Astana Medical University, Nur-Sultan, the Republic of Kazakhstan;

<sup>3</sup>Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic;

<sup>4</sup>Akhunbaev Kyrgyz State Medical Academy, Bishkek, the Kyrgyz Republic;

<sup>5</sup>Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan;

<sup>6</sup>Asfendiyarov Kazakh National Medical University, Almaty, the Republic of Kazakhstan

## ABSTRACT

**Relevance:** Every year, 732,210 new cases of RC are registered globally, with an incidence of 7.6 per 100,000. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with an asymptomatic cancer diagnosis.

**The aim was to** assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics.

**Methods:** The data obtained from the Ministry of Healthcare of the Republic of Kazakhstan concerning RC (Form no. 7) was retrospectively studied by descriptive and analytical epidemiology methods. The component method was used to analyze RC incidence dynamics based on the number of cases from 2010 to 2020.

**Results:** From 2010 to 2020, the risk of getting RC went down. An increase in incidence in 2010-2020 (+24.8%) was lower than in the preCOVID period of 2010-2019 (+37.2%). We found a sharp decrease in RC incidence from 2019 to 2020. The overall decrease was 0.89‰ due to changes in the age structure of the population ( $\sum A_A = +0.13\text{‰}$ ), the risk of getting RC ( $\sum A_R = -1.02\text{‰}$ ), and the combined impact of age structure and the risk of getting RC ( $\sum A_{AR} = -0.002\text{‰}$ ). According to the component analysis, 1,662 patients with RC were expected in 2020; instead, only 1,471 cases were registered. Such a decline in cases was mainly due to a reduced risk of getting RC.

**Conclusions:** The analysis of RC incidence trends in Kazakhstan shows a negative impact of COVID-19 on cancer care indicators and effectiveness. All oncological examinations were strengthened with the resumption of work after COVID restrictions. However, the number of screening visits remains lower than in previous years. Untimely diagnosis can increase the number of cases of late-stage CRC and an overall loss of years of life due to the lack of proper treatment. However, these forecasts can be mitigated by proper follow-up.

**Keywords:** rectal cancer (RC), incidence, trends, COVID-19, Kazakhstan.

**Introduction:** According to the latest WHO data (2020), colorectal cancer (CRC) is the 3rd most common globally, with an incidence of 19.5 per 100,000. The number of patients with rectal cancer (RC) was 732,210 cases, with an incidence of 7.6 per 100,000 [1]. RC differs from colon cancer due to the narrow anatomical boundaries of the pelvis, the proximity of the genitourinary organs and nerves, and the mechanism of the anal sphincter. The 5-year survival rate in general for RC (all stages) is about 53%, and unfortunately, it remains low, despite progress in diagnostic and therapeutic measures [2].

Population screening plays an essential role in detecting pathology and increasing morbidity rates. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with symptomatic cancer [3]. National professional societies have issued recommendations (the American Society of Clinical Oncology, the American Society of Breast Surgeons, the American College of Radiology, and the American Society of Colposcopy and Cervical Pathology) to postpone regular cancer screening until medical institutions resume preventive visits [4-6]. Patients with well-recognized alarming symptoms, such as rectal bleeding, will continue to seek primary care. However, when COVID-19 is at the forefront, patients may not pay due at-

tention to the vague primary symptoms of cancer, such as fatigue, changes in bowel function, and weight loss [7]. Years before the pandemic, the rates of population screening for CRC among adults with an average age-appropriate risk increased [8]. During the pandemic, an analysis of national cancer screening schemes revealed a sharp 86% drop in the rates for CRC screening [9].

In a recent study on CRC incidence in Kazakhstan, it was found that the incidence is 16.9 per 100,000 population and tends to increase [10]. Therefore, there is an interest in studying each section of the large intestine separately.

The study aimed to assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics (2020).

**Material and Methods:** The material of the study was the data of the Ministry of Health (MoH) of the Republic of Kazakhstan concerning RC (Form no. 7). The retrospective study employed descriptive and analytical methods of epidemiology. The component method in this study was used to decompose the increase in the number of cases in the same population in different periods. There are seven components of the increase in the number of cases; the first three are associated with changes in the population,

its age structure, and a combined impact of these factors. The 4<sup>th</sup> component is an actual increase in the number of patients with oncological pathology due to a change in the morbidity risk index only. The other three components are associated with the risk of getting a malignant neoplasm, population growth, changes in its age structure, and the impact of all these three factors. Thus, the last four components are associated with an increase in the risk of developing the disease. The "risk of getting sick" covers the whole range of reasons that can increase, decrease, or stabilize morbidity rates [11]. The component method was used to analyze the dynamics of RC incidence based on the number of cases registered in 2010-2019, 2010-2020, and 2019-2020. Extensive and intensive indicators were calculated using the generally accepted methods of biomedical

statistics [12, 13]. The annual averages (M), mean error (m), 95% confidence interval (95% CI), and average annual upward/downward rates (T%) were calculated.

The following symbols and abbreviations were used in this article: AN – absolute number; ASP ( $\Delta_A$ ) – the age structure of the population; PN ( $\Delta_P$ ) – population number; RAI ( $\Delta_R$ ) – risk of getting RC;  $R^2$  – the value of the approximation confidence; I – the incidence; ‰ – percent mille.

**Results:** During the study period (2010-2020), 15,552 new cases of RC were registered in the country. RC's annual average incidence in Kazakhstan amounted to  $8.1 \pm 0.2\text{‰}$  (95% CI=7.8-8.3) per 100,000 population. Over time, the index increased from  $7.2 \pm 0.2\text{‰}$  (95% CI=6.8-7.6) in 2010 to  $7.8 \pm 0.2\text{‰}$  (95% CI=7.4-8.2) in 2020, with a statistically significant difference ( $t=2.12$ ;  $p=0.034$ ) (Figure 1).




Figure 1 – Trends of RC incidence in Kazakhstan, 2010-2020

To identify the components that influenced the incidence of RC during this period, we will analyze the pre-covid

period (2010 to 2019), the covid period (2019 and 2020), and the entire period in general (2010 to 2020) (see Table 1).

Table 1 – Influencing components on the number of cases of RC, 2010-2020

Components of growth in the number of cases due to:	2010 to 2019			2010 to 2020			2019 to 2020		
	AN	% growth		AN	% growth		AN	% growth	
		to ( $n_2-n_1$ )	to $n_1$		to ( $n_2-n_1$ )	to $n_1$		to ( $n_2-n_1$ )	to $n_1$
1. Growth PN. $\Delta_P = \frac{N_1-N_2}{N_1} n_1$	+158	+36.2	+13.4	+176	+60.2	+14.9	+21	+14.5	+1.3
2. Changes ASP. $\Delta_A = \frac{N_1}{N_2} (E(n_2) - n_2 - \Delta_H)$	+126	+28.8	+10.7	+141	+48.2	+11.9	+23	+16.0	+1.4
3. Combined effect of changes in PN+ASP. $\Delta_{PA} = \frac{N_2-N_1}{N_1} \Delta_A$	+17	+3.9	+1.4	+21	+7.2	+1.8	+0.3	+0.2	0.0
	$\Sigma_{1-3} = +68.9$	$\Sigma_{1-3} = +25.6$		$\Sigma_{1-3} = +115.6$	$\Sigma_{1-3} = +28.6$		$\Sigma_{1-3} = +30.7$	$\Sigma_{1-3} = +2.8$	
4. Change of RAI. $\Delta_R = N_1(P_2^c - P_1^c) \times 10^{-5}$	+85	+19.4	+7.2	-51	-17.5	-4.3	-188	-128.8	-11.6
5. Combined effect of changes of RAI+PN. $\Delta_{RP} = \frac{N_2-N_1}{N_1} \Delta_R$	+11	+2.6	+1.0	-8	-2.6	-0.6	-2	-1.7	-0.2
6. Combined effect of changes of RAI+ASP. $\Delta_{RA} = \frac{N_2-N_1}{N_1} \Delta_R$	+35	+8.0	+3.0	+11.3	+3.9	+1.0	-0.3	-0.2	0.0
7. Combined effect of the changes RAI+PN+ASP. $\Delta_{RAP} = \frac{N_1}{N_2} (n_2 - n_1 - \Sigma_{x=1}^5)$	+5	+1.1	+0.4	+1.7	+0.6	+0.1	0.0	0.0	0.0
	$\Sigma_{4-7} = +31.1$	$\Sigma_{4-7} = +11.6$		$\Sigma_{4-7} = -15.6$	$\Sigma_{4-7} = -3.9$		$\Sigma_{4-7} = +130.7$	$\Sigma_{4-7} = -11.8$	
Total $\Sigma_{1-7}$	+438	100.0	+37.2	+292	100.0	+24.8	-146	100.0	-9.0

The total increase in the pre-covid period was +1.51‰ and depended on the changes in the age structure of the population ( $\Sigma\Delta_A=+0.77\%$ ), the risk of getting RC ( $\Sigma\Delta_R=+0.52\%$ ), and the combined impact of the age structure and the risk of getting RC ( $\Sigma\Delta_{AR}=+0.22\%$ ). At the same time, the average annual growth rate of the aligned indicator was  $T=+1.6\%$ , and the approximation confidence value was close to 1 ( $R^2=0.694$ ).

According to the calculations of the component analysis (2010-2019), considering all the above factors, 1,481 patients were expected in 2019. Still, the actual number of patients amounted to 1,617. The number of patients with RC in Kazakhstan grew from 2010 to 2019. After the component analysis, we attributed the growth in the number of patients mainly to the population growth, changes in the age structure, and changes in the risk of getting RC (see Table 1).

If we analyze the period from 2010 to 2020 (Table 1), we can see an increase in the number of patients but an apparent decrease in the risk of getting RC. An increase of cases by 24.8% was lower compared to an increase of 37.2% in 2010-2019.

Further comparing 2019 and 2020, we found that the incidence of RC has decreased dramatically. The total decrease was -0.89‰ and depended on changes in the age structure of the population ( $\Sigma\Delta_A=+0.13\%$ ), the risk of getting RC ( $\Sigma\Delta_R=-1.02\%$ ) and the combined impact of the age structure and the risk of getting RC ( $\Sigma\Delta_{AR}=-0.002\%$ ). As you can see, the decrease was mainly affected by a lower risk of getting RC.

According to the calculations of the component analysis, 1,662 patients were expected in 2020. Instead, the number of patients decreased and amounted to 1,471. Thus, the RC incidence has decreased due to a lower risk of getting this disease (-11.6% of the total decrease by -9.0%) (see Table 1).

**Discussion:** Non-urgent laboratory and imaging tests and scheduled procedures were suspended worldwide to help medical institutions cope with the COVID-19 outbreak, avoid overloading the healthcare system, save resources, and reduce the risk of transmission [14]. Fear of infection could promote many deaths due to delays in diagnosing life-threatening diseases. These restrictions have also been introduced in our republic. As a result, as it turned out in our study, the number of detected cases of RC decreased in 2020. There is data on a significant decrease in the number of patients undergoing cancer screening tests; respectively, the number of subsequent diagnoses of cancerous and precancerous lesions during the COVID-19 pandemic was reduced [15-18].

**Conclusion:** Thus, the analysis of trends in rectal cancer incidence in Kazakhstan shows the negative impact of COVID-19 on the indicators and effectiveness of the cancer care service since the number of newly identified cases has decreased and the incidence declined. Ultimately, a decrease in the number of people undergoing screening might lead to delayed detection of precancerous lesions and CRC, thus increasing CRC incidence or the proportion of later stages at detection. With the resumption of work after the restrictions associated with COVID-19, all cancer screenings were

intensified. However, the number of cancer screening visits remains significantly lower than in the previous years. The long-term consequences of a delay in diagnostics can lead to a devastating increase in the number of cases of late-stage CRC and an overall loss of years of life due to the lack of appropriate treatment for these patients. However, these forecasts can be mitigated if proper catch-up surveys are carried out.

## References

1. Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M. *Global Cancer Observatory: Cancer Today*. – Lyon, France: International Agency for Research on Cancer, 2020. <https://gco.iarc.fr/today/data/factsheets/cancers/9-Rectum-fact-sheet.pdf>. 01.03.2022;
2. Madbouly K.M., Hussein A.M., Abdelzاهر E. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer. // *Am. J. Surg.* – 2014. – Vol. 208(3). – P. 332-341. <https://doi.org/10.1016/j.amjsurg.2013.10.023>;
3. American Cancer Society. *Common questions about the new coronavirus outbreak* // [www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html](http://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html). 01.03.2022;
4. American Society of Clinical Oncology. *Cancer screening, diagnosis, staging and surveillance* // [www.asco.org/asco-coronavirus-resources/care-individuals-cancer-during-covid-19/cancer-screening-diagnosis-staging](http://www.asco.org/asco-coronavirus-resources/care-individuals-cancer-during-covid-19/cancer-screening-diagnosis-staging). 02.03.2022;
5. American Society for Colposcopy and Cervical Pathology. *Interim guidance for timing of diagnostic and treatment procedures for patients with abnormal cervical screening tests* // [www.asccp.org/covid-198](http://www.asccp.org/covid-198). 02.03.2022;
6. The American Society of Breast Surgeons. *ASBrS and ACR Joint Statement on Breast Screening Exams During the COVID-19 Pandemic* // [www.breastsurgeons.org/news/?id=45](http://www.breastsurgeons.org/news/?id=45). 02.03.2022;
7. Jones D., Neal R.D., Duffy S.R.G., Scott S.E., Whitaker K.L., Brain K. *Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care* // *Lancet Oncol.* – 2020. – Vol. 21(6). – P. 748-750. [https://doi.org/10.1016/S1470-2045\(20\)30242-4](https://doi.org/10.1016/S1470-2045(20)30242-4);
8. National Cancer Institute. *Cancer Trends Progress Report. Online Summary of Trends in US Cancer Control Measures Centers for Disease Control and Prevention: colorectal cancer screening* // [progressreport.cancer.gov/detection/colorectal](http://progressreport.cancer.gov/detection/colorectal). 02.03.2022;
9. EPIC Health Research Network (EHRN). *Preventive cancer screenings during COVID-19 pandemic* // [ehrn.org/wp-content/uploads/Preventive-Cancer-Screenings-during-COVID-19-Pandemic.pdf](http://ehrn.org/wp-content/uploads/Preventive-Cancer-Screenings-during-COVID-19-Pandemic.pdf). 02.03.2022;
10. Mauyenova D., Zhadykova Y., Khozhayev A., Turebayev D., Kulmirzayeva D., Urazova S., Nurtazinova G., Kuandykov Y., Amanshayeva A., Sakhanov S., Bukeyeva Z., Openko V., Orzabayev S., Kozhakhmetov S., Bilyalova Z., Igissinova G., Alireza Mosavi Jarrahi A., Igissinov N. *Trends of Colorectal Cancer Incidence in Kazakhstan* // *Asian Pac. J. Cancer Prev.* – 2021. – Vol. 22(10). – P. 3405-3414. <https://doi.org/10.31557/APJCP.2021.22.10.3405>;
11. Двойрин В.В., Аксель Е.М. Компонентный анализ динамики заболеваемости злокачественными новообразованиями (методические рекомендации). – М., 1987. – 10 с. [Dvoyrin V.V., Aksel E.M. Komponentnyj analiz dinamiki zabollevaemosti zlokachestvennyimi novoobrazovaniyami (metodicheskie rekomendacii). – М., 1987. – 10 s. (in Russ.);]
12. Гланц С. Медико-биологическая статистика. Пер. с англ. — М.: Практика, 1998. — 459 с. [Glanc S. Medikobioologicheskaya statistika. Per. s angl. — М.: Praktika, 1998. — 459 s. (in Russ.);]
13. Организация онкологической службы в России (методические рекомендации, пособия для врачей) / под ред. В.И. Чиссова, В.В. Старинского, Б.Н. Ковалева. – Часть 2. – М.: ФГУ МНИОИ им. П.А. Герцена Росмедтехнологий, 2007. — 663 с. [Organizatsiya onkologicheskoy sluzhby v Rossii (metodicheskie rekomendacii, posobiya dlya vrachej) / pod red. V.I. Chissova, V.V. Starinskogo, B.N. Kovaleva. – Chast' 2. – М.: FGU MNIIOI im. P.A. Gercena Rosmedtexnologij, 2007. — 663 s. (in Russ.);]
14. Iacobucci G. *COVID-19: all non-urgent elective surgery is suspended for at least three months in England* // *BMJ.* – 2020. – Vol. 368. – P. 1106. <https://doi.org/10.1136/bmj.m1106>;
15. Bakouny Z., Paciotti M., Schmidt A.L., Lipsitz S.R., Choueiri T.K., Trinh Q.D. *Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic* // *JAMA Oncol.* – 2021. – Vol. 7(3). – P. 458-460. <https://doi.org/10.1001/jamaoncol.2020.7600>;

16. Australian Government. Cancer Australia. Review of the impact of COVID-19 on medical services and procedures in Australia utilizing MBS data: skin, breast and colorectal cancers, and telehealth services // [www.canceraustralia.gov.au/sites/default/files/publications/review-impact-covid-19-medical-services-and-procedures-australia-utilising-mbs-data-skin-breast-and-colorectal-cancers-and-telehealth-services](http://www.canceraustralia.gov.au/sites/default/files/publications/review-impact-covid-19-medical-services-and-procedures-australia-utilising-mbs-data-skin-breast-and-colorectal-cancers-and-telehealth-services) // <https://doi.org/10.1136/bmjopen-2020-043828>; 03.03.2022;

17. Lai A.G., Pasea L., Banerjee A., Hall G., Denaxas S., Chang W.H., Katsoulis M., Williams B., Pillay D., Noursadeghi M., Linch D., Hughes D., Forster M.D., Turnbull C., Fitzpatrick N.K., Boyd K., Foster G.R.,

Enver T., Nafilyan V., Humberstone B., Neal R.D., Cooper M., Jones M., Pritchard-Jones K., Sullivan R., Davie C., Lawler M., Hemingway H. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study // *BMJ Open*. – 2020. – Vol. 10(11). – P. e043828. <https://doi.org/10.1136/bmjopen-2020-043828>;

18. Logan R.F., Patnick J., Nickerson C., Coleman L., Rutter M.D., von Wagner C. English Bowel Cancer Screening Evaluation Committee Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests // *Gut*. – 2012. – Vol 61. – P. 1439-1446. <https://doi.org/10.1136/gutjnl-2011-300843>.

## ТҰЖЫРЫМ

### COVID-19-дың ДЫҢ ҚАЗАҚСТАНДАҒЫ ТІК ІШЕК ОБЫРЫНА ӘСЕРІ: КОМПОНЕНТТІК ТАЛДАУ НӘТИЖЕЛЕРІ

Ж.Б. Тельманова<sup>1-3</sup>, А.К. Аксарин<sup>1-4</sup>, А.О. Оралбек<sup>5</sup>, С.Т. Орозбаев<sup>2</sup>, К.Т. Құлаев<sup>5</sup>, Н.З. Шапамбаев<sup>5</sup>, Е.К. Қуандықов<sup>5</sup>, З.А. Билялова<sup>1</sup>, Г.С. Игисинава<sup>6,1</sup>, К.Р. Рустемова<sup>2,1</sup>, И.О. Құдайбергенова<sup>4,3</sup>, Н.С. Игисинов<sup>1-3</sup>

<sup>1</sup>Central Asian Institute for Medical Research, Нұр-Сұлтан, Қазақстан Республикасы;

<sup>2</sup>Астана медицина университеті, Нұр-Сұлтан, Қазақстан Республикасы;

<sup>3</sup>Eurasian Institute for Cancer Research, Бішкек, Қырғыз Республикасы;

<sup>4</sup>Ахунбаев атындағы Қырғыз мемлекеттік медицина академиясы, Бішкек, Қырғыз Республикасы;

<sup>5</sup>Қ.А. Ясауи атындағы Халықаралық қазақ-түрік университеті, Шымкент, Қазақстан Республикасы;

<sup>6</sup>Асфендияров атындағы Қазақ ұлттық медицина университеті, Алматы, Қазақстан Республикасы

**Өзектілігі:** Жыл сайын тік ішек обырымен ауыратын 732 210 жағдай тіркеледі, сырқаттанушылық 100 000 адамға 7,6 құрайды. COVID-19 пандемиясы скринингке, жағдайларды анықтауға және асимптоматикалық қатерлі ісік диагнозы бар науқастарды бағыттауға әсер етті.

**Зерттеудің мақсаты** – COVID-пандемиясы басталғанға дейін және оның кезеңінде Қазақстан тұрғындары арасында тік ішек обырының сырқаттанушылық динамикасын бағалау.

**Әдістері:** Зерттеу материалы Қазақстан Республикасы Денсаулық сақтау министрлігінің тік ішек обырына қатысты деректері (7-нысан) болды. Ретроспективті зерттеуде эпидемиологияның сипаттамалық және аналитикалық әдістері қолданылды. Компоненттік әдіс 2010 жылдан 2020 жылға дейін болған жағдайлардың санына негізделген тік ішек қатерлі ісігінің динамикасын талдау үшін қолданылды.

**Нәтижелер:** 2010-2020 жылдардағы деректерді талдай отырып, біз тік ішек обырымен ауру қауіпінің айқын төмендеуін анықтадық. 2010 жылдан бастап 2020 жылға дейін байқалған сырқаттанушылықтың өсуі (+24,8%) ковид алды 2010-2019 жылдарға (+37,2%) қарағанда төмен болды. Әрі қарай, біз 2019 жылдан 2020 жылға дейін тік ішек обырымен сырқаттанушылықтың күрт төмендегенін байқадық. Жалпы төмендеу –0,89‰ болды және халықтың жас құрылымының өзгеруіне ( $\Sigma DA = +0,13\%$ ), ауру қауіпі ( $\Sigma \Delta R = -1,02\%$ ) және жас құрылымы мен ауру қауіпінің жиынтық әсері ( $\Sigma \Delta AR = -0,002\%$ ) байланысты болды. Компоненттік талдау есептеулеріне сәйкес, 2020 жылы 1662 тік ішек обыры бар науқас күтілген, бірақ оның орнына пациенттер саны 1471 болды. Аталған жағдайлар санының төмендеуі тік ішек обырымен ауру қауіпінің төмендеуімен байланысты болды.

**Тұжырымдар:** Осылайша, Қазақстанда тік ішек обырымен сырқаттанушылық динамикасын талдау COVID-19-дың онкологиялық қызметтің көрсеткіштері мен тиімділігіне теріс әсерін көрсетеді. COVID-19-ға байланысты шектеулерден кейін жұмысты қайта бастаған кезде барлық онкологиялық тексерулер күшейтілді. Алайда, қатерлі ісік скринингіне бару саны алдыңғы жылдарға қарағанда едәуір төмен болып қала береді. Диагностдың кеісізгі тоқ ішек қатерлі ісігінің соңғы кезеңдерінің ұлғаюына және осы науқастарда тиісті емнің болмауына байланысты өмір сүру ұзақтығының жалпы төмендеуіне әкелуі мүмкін. Дегенмен, егер тиісті бақылау жүргізілсе, бұл болжамдарды жақсартуға болады.

**Түйінді сөздер:** тік ішек қатерлі ісігі, сырқаттанушылық, тренд, Covid-19, Қазақстан.

## АННОТАЦИЯ

### ВЛИЯНИЕ COVID-19 НА ЗАБОЛЕВАЕМОСТЬ РАКОМ ПРЯМОЙ КИШКИ В КАЗАХСТАНЕ: РЕЗУЛЬТАТЫ КОМПОНЕНТНОГО АНАЛИЗА

Ж.Б. Тельманова<sup>1-3</sup>, А.К. Аксарин<sup>1-4</sup>, А.О. Оралбек<sup>5</sup>, С.Т. Орозбаев<sup>2</sup>, К.Т. Құлаев<sup>5</sup>, Н.З. Шапамбаев<sup>5</sup>, Е.К. Қуандықов<sup>5</sup>, З.А. Билялова<sup>1</sup>, Г.С. Игисинава<sup>6,1</sup>, К.Р. Рустемова<sup>2,1</sup>, И.О. Құдайбергенова<sup>4,3</sup>, Н.С. Игисинов<sup>1-3</sup>

<sup>1</sup>Central Asian Institute for Medical Research, Нұр-Сұлтан, Республика Казахстан;

<sup>2</sup>Медицинский университет Астана, Нұр-Сұлтан, Республика Казахстан;

<sup>3</sup>Eurasian Institute for Cancer Research, Бишкек, Кыргызская Республика;

<sup>4</sup>Кыргызская государственная медицинская академия им. Ахунбаева, Бишкек, Кыргызская Республика;

<sup>5</sup>Международный казахско-турецкий университет имени Ходжи Ахмеда Ясави, Шымкент, Республика Казахстан;

<sup>6</sup>Казахский национальный медицинский университет им. Асфендиярова, Алматы, Республика Казахстан

**Актуальность:** Ежегодно в мире регистрируется 732 210 новых случаев рака прямой кишки (РПК), заболеваемость составляет 7,6 на 100 000. Пандемия COVID-19 повлияла на скрининг, выявление случаев заболевания и направление пациентов с бессимптомным диагнозом рака.

**Цель исследования** – оценить динамику заболеваемости населения Казахстана раком прямой кишки до и во время пандемии COVID.

**Методы:** В ретроспективном исследовании данных Министерства здравоохранения Республики Казахстан о новых случаях РПК, полученных из формы №7, использовались описательные и аналитические методы эпидемиологии. Для анализа динамики заболеваемости на основе количества случаев заболевания с 2010 по 2020 год был использован компонентный метод.

**Результаты:** Анализируя данные за 2010-2020 гг., мы обнаружили явное снижение риска заболевания РПК. Рост заболеваемости, наблюдавшийся с 2010 по 2020 гг. (+24,8%), был ниже, чем в доковидном периоде 2010-2019 гг. (+37,2%). Далее, мы обнаружили резкое

снижение заболеваемости РПК с 2019 по 2020 гг. Общее снижение составило  $-0,89\%$  и зависело от изменений в возрастной структуре населения ( $\sum DA = +0,13\%$ ), риска заболевания ( $\sum DR = -1,02\%$ ) и совокупного влияния возрастной структуры и риска заболевания ( $\sum DAR = -0,002\%$ ). Согласно расчетам компонентного анализа, в 2020 году ожидалось 1662 пациента с РПК, но вместо этого число пациентов составило 1471. Указанное снижение числа случаев произошло в основном из-за влияния риска заболевания РПК.

**Заключение:** Таким образом, анализ динамики заболеваемости раком прямой кишки в Казахстане свидетельствует о негативном влиянии COVID-19 на показатели и эффективность работы онкологической службы. С возобновлением работы после ограничений, связанных с COVID-19, все онкологические обследования были усилены. Тем не менее, количество посещений для скрининга рака остается значительно ниже, чем в предыдущие годы. Несвоевременная диагностика может привести к увеличению числа случаев поздних стадий КРР и общей потере лет жизни из-за отсутствия надлежащего лечения этих пациентов. Однако эти прогнозы можно смягчить, если проводить надлежащее последующее наблюдение.

**Ключевые слова:** рак прямой кишки (РПК), заболеваемость, тренды, COVID-19, Казахстан.

---

**Transparency of the study:** Authors take full responsibility for the content of this article.

**Conflict of interests:** Authors declare no conflict of interest.

**Financing:** Authors declare no financing of the study.

**Authors' input:** contribution to the study concept – Igissinov N.S., Kudaibergenova I.O.; study design – Igissinova G.S., Bilalova Z.A., Rustemova K.R.; execution of the study – Telmanova Zh. B., Kulayev K.T., Shapambayev N.Z.; interpretation of the study – Orozbaev S.T., Telmanova Zh. B., Kuandykov Y.K.; preparation of the manuscript – Axarin A.K., Oralbek A.O., Telmanova Zh.B.

**Authors' data:**

**Telmanova Zhansaya Bekmakanovna** – Researcher at the Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan; Researcher at the Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic; 6<sup>th</sup> year intern, Faculty of General Medical Practice, Astana Medical University, the Republic of Kazakhstan, e-mail: telmanova.zhansaya@gmail.com, ID ORCID: <https://orcid.org/0000-0002-2364-6520>;

**Axarin Askhat Kapezovich** – Researcher at the Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan; Researcher at the Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic; Assistant of the Department of Surgical Diseases with courses of Cardiothoracic and Maxillofacial Surgery, Astana Medical University, the Republic of Kazakhstan; Postgraduate student of Akhunbaev Kyrgyz State Medical Academy, Bishkek, the Kyrgyz Republic, e-mail: dr.axarin@gmail.com, ID ORCID: <https://orcid.org/0000-0001-8893-2432>;

**Oralbek Ayzhan Oralbekyzy** – Master of Medicine, Lecturer at the Department of General Medical Practice No. 1, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan, e-mail: oralbek.ayzhan@mail.ru, ID ORCID: <https://orcid.org/0000-0002-8496-6202>;

**Orozbaev Serikbay Tleugabylovich** – Candidate of Medical Sciences, Ass. Prof. at the Department of Surgical Diseases with courses of Cardiothoracic and maxillofacial surgery, Astana Medical University, the Republic of Kazakhstan, e-mail: orazbaev\_s.t@mail.ru, ID ORCID: <https://orcid.org/0000-0003-3895-0426>;

**Kulayev Kuanish Tagaevich** – Candidate of Medical sciences, Ass. Prof. at the Department of General Medical Practice No. 1, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan, e-mail: kulayev\_k\_t@mail.ru, ID ORCID: <https://orcid.org/0000-0002-3886-7238>;

**Shapambayev Nasriddin Zaitovich** – Candidate of Medical Sciences, Senior Lecturer at the Department of General Medical Practice No. 1, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan, e-mail: shapambayev@mail.ru, ID ORCID: <https://orcid.org/0000-0002-1986-5333>;

**Kuandykov Yerlan Kenesbaevich** – Candidate of Medical Sciences, Ass. Prof. at the Department of General Medical Practice No. 1, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, the Republic of Kazakhstan, e-mail: gipokrat78@mail.ru, ID ORCID: <https://orcid.org/0000-0002-7966-1471>;

**Bilalova Zarina Aronovna** – PhD Public Health, Ass. Prof., Chief Researcher, Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan, e-mail: z.bilyalova@gmail.com, ID ORCID: <https://orcid.org/0000-0002-0066-235X>;

**Igissinova Gulnur Saginbekovna** – Candidate of Medical Sciences, Ass. Prof. at the Department of Oncology, Asfendiyarov Kazakh National Medical University, Almaty, the Republic of Kazakhstan; Senior research worker at the Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan, e-mail: gulnurs@list.ru, ID ORCID: <https://orcid.org/0000-0001-6881-2257>;

**Rustemova Kulsara Rustembekovna** – Doctor of Medical Sciences, Prof. at the Department of Surgical Diseases with courses of Cardiothoracic and maxillofacial surgery, Astana Medical University, Nur-Sultan, the Republic of Kazakhstan; Senior research worker at the Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan, e-mail: rustemovak@mail.ru, ID ORCID: <https://orcid.org/0000-0002-8853-9267>;

**Kudaibergenova Indira Orazbaevna** – Doctor of Medical Sciences, Prof., Rector of Akhunbaev Kyrgyz State Medical Academy, Bishkek, the Kyrgyz Republic; Senior research worker at the Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic, e-mail: k\_i\_o2403@mail.ru, ID ORCID: <https://orcid.org/0000-0003-3007-8127>;

**Igissinov Nurbek Saginbekovich (corresponding author)** – Doctor of Medical Sciences, Head of Central Asian Institute for Medical Research, Nur-Sultan, the Republic of Kazakhstan; Prof. at the Department of Surgical Diseases with courses of Cardiothoracic and maxillofacial surgery, Astana Medical University; Vice President of the Eurasian Institute for Cancer Research, Bishkek, the Kyrgyz Republic, Astana Medical University, the Republic of Kazakhstan, 010000, Nur-Sultan city, Beybitshilik str., 49a, tel. +77024293421, e-mail: n.igissinov@gmail.com, ID ORCID: [noID ORCID: https://orcid.org/0000-0002-2517-6315](https://orcid.org/0000-0002-2517-6315).